Screener
NeoGenomics NEO Q2 2026 earnings
Reported July 28, 2026 · After market close
Revenue$201.7MBeat by $4.7M
Adjusted EPS$0.05Beat by $0.02
Revenue estimate$196.9M
EPS estimate$0.03
“Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term profitable growth, while investing in our business and expanding our suite of on-market testing solutions for patients and providers.”
Next report
Oct 27, 2026 (in a month)Revenue estimate$205.9M
EPS estimate$0.06
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did NeoGenomics report Q2 2026 earnings?
- NeoGenomics (NEO) reported Q2 2026 earnings on July 28, 2026 after market close.
- What were NeoGenomics's Q2 2026 revenue and EPS?
- NeoGenomics reported revenue of $201.7M and adjusted eps of $0.05 for Q2 2026.
- Did NeoGenomics beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $196.9M by $4.7M. EPS beat the consensus estimate of $0.03 by $0.02.
- How did NeoGenomics's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 11.2% from $181.3M a year earlier.
- Where can I find NeoGenomics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001077183-26-000058) and the 10-Q periodic report (0001077183-26-000059) directly on SEC EDGAR. The filing index links above go to sec.gov.
